Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis

References

• Takayanagi H. Osteoimmunological insight into bone damage in rheumatoid arthritis. Mod Rheumatol 2005;15:225–31.
   PubMedGoogle Scholar
• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356–61.
   PubMed Web of Science ®Google Scholar
• Sato K, Takayanagi H. Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr Opin Rheumatol 2006;18:419–26.
   PubMed Web of Science ®Google Scholar
• Takayanagi H. Infl ammatory bone destruction and osteoimmunology. J Periodontal Res 2005;40:287–93.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473–88.
   PubMed Web of Science ®Google Scholar
• Le Loet X, Berthelot JM, Cantagrel A, Combe B, De Bandt M, Fautrel B, et al. Clinical practice decision tree for the choice of the fi rst disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology. Ann Rheum Dis 2006;65:45–50.
   PubMedGoogle Scholar
• Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999;58:220–5.
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675–81.
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003;4(8):638–49.
   PubMed Web of Science ®Google Scholar
• Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337–42.
   Google Scholar
• Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345–57.
   PubMed Web of Science ®Google Scholar
• Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002;20: 795–823.
   Google Scholar
• Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 2005;83:170–9.
   PubMed Web of Science ®Google Scholar
• Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004;428:758–63.
   PubMed Web of Science ®Google Scholar
• Ross FP, Teitelbaum SL. Alphavbeta3 and macrophage colonystimulating factor: partners in osteoclast biology. Immunol Rev 2005;208:88–105.
   PubMed Web of Science ®Google Scholar
• Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006;24:33–63.
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889–901.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95: a3597–602.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology 1988;123:2600–2.
   PubMed Web of Science ®Google Scholar
• Urushibara M, Takayanagi H, Koga T, Kim S, Isobe M, Morishita Y, et al. The antirheumatic drug lefl unomide inhibits osteoclastogenesis by interfering with receptor activator of NF-�B ligandstimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum 2004;50:794–804.
   PubMedGoogle Scholar
• Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000;43:2143–51.
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor kB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000;43:259–69.
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Oda H, Yamamoto S, Kawaguchi H, Tanaka S, Nishikawa T, et al. A new mechanism of bone destruction in rheumatoid arthritis: synovial fi broblasts induce osteoclastogenesis. Biochem Biophys Res Commun 1997;240:279–86.
   PubMed Web of Science ®Google Scholar
• Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689–99.
   PubMed Web of Science ®Google Scholar
• Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-�-mediated joint destruction. J Clin Invest 2002;110:1419–27.
   Google Scholar
• Takayanagi H, Juji T, Miyazaki T, Iizuka H, Takahashi T, Isshiki M, et al. Suppression of arthritic bone destruction by adenovirusmediated csk gene transfer to synoviocytes and osteoclasts. J Clin Invest 1999;104:137–46.
   PubMed Web of Science ®Google Scholar
• Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402: 304–9.
   PubMed Web of Science ®Google Scholar
• Lubberts E, Joosten LA, Chabaud M, van Den Bersselaar L, Oppers B, Coenen-De Roo CJ, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000;105: 1697–710.
   Google Scholar
• Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: the fi rst step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum 2006;54:1366–77.
   PubMed Web of Science ®Google Scholar
• Sekiguchi N, Kameda H, Amano K, Takeuchi T. Effi cacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. Mod Rheumatol 2006;16:85–91.
   PubMedGoogle Scholar
• Nagashima M, Shu G, Yamamoto K, Yamahatsu S, Yoshino S. The ability of disease modifying antirheumatic drugs to induce and maintain improvement in patients with rheumatoid arthritis. epidemiology of DMARDs treatment in Japan. Clin Exp Rheumatol 2005;23:27–35.
   Google Scholar
• Tsuji F, Aono H, Okamoto M, Sasano M. Bucillamine, A unique anti-rheumatic drug. Curr Top Pharmacol [in press].
   Google Scholar
• Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-�. Nature 2000;408:600–5.
   PubMed Web of Science ®Google Scholar
• Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, Nakashima K, et al. NFAT and Osterix cooperatively regulate bone formation. Nat Med 2005;11:880–5.
   PubMed Web of Science ®Google Scholar
• Lee CK, Lee EY, Chung SM, Mun SH, Yoo B, Moon HB. Effects of disease-modifying antirheumatic drugs and anti-infl ammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor �B, osteoprotegerin, and receptor activator of nuclear factor �B ligand. Arthritis Rheum 2004;50:3831–43.
   PubMed Web of Science ®Google Scholar
• Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, et al. Autoamplifi cation of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005;202:1261–9.
   PubMed Web of Science ®Google Scholar
• Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673–82.
   PubMed Web of Science ®Google Scholar
• Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 1984;27:968–75.
   PubMed Web of Science ®Google Scholar
• Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS. Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 2005;1:47–54.
   Google Scholar
• Dong C. Diversifi cation of T-helper-cell lineages: fi nding the family root of IL-17-producing cells. Nat Rev Immunol 2006;6:329–33.
   Google Scholar
• Munakata Y, Iwata S, Dobers J, Ishii T, Nori M, Tanaka H, et al. Novel in vitro effects of bucillamine: inhibitory effects on proinfl ammatory cytokine production and transendothelial migration of T cells. Arthritis Rheum 2000;43:1616–23.
   PubMedGoogle Scholar
• Aono H, Hasunuma T, Fujisawa K, Nakajima T, Yamamoto K, Mita S, et al. Direct suppression of human synovial cell proliferation in vitro by salazosulfapyridine and bucillamine. J Rheumatol 1996;23:65–70.
   PubMed Web of Science ®Google Scholar
• Liptay S, Bachem M, Hacker G, Adler G, Debatin KM, Schmid RM. Inhibition of nuclear factor �B and induction of apoptosis in T-lymphocytes by sulfasalazine. Br J Pharmacol 1999;128:1361–9.
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, et al. Infl iximab in active early rheumatoid arthritis. Ann Rheum Dis 2004;63:149–55.
   PubMed Web of Science ®Google Scholar
• Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, et al. Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study. Mod Rheumatol 2005;15:323–8.
   PubMedGoogle Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint infl ammation in rheumatoid arthritis. N Engl J Med 2001;344:907–16.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Anti-TNF� therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163–96.
   PubMed Web of Science ®Google Scholar